We are live on
!
Find out more
PR
PSP Research Portfolio holdings
AUM
$188M
This Fund
S&P 500
This Quarter
Est. Return
+15.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$188M
AUM Growth
+$46.6M
(+33%)
Cap. Flow
+$25.8M
Cap. Flow
% of AUM
13.71%
Top 10 Holdings %
Top 10 Hldgs %
88.03%
Holding
89
New
10
Increased
1
Reduced
31
Closed
14
Avg Time Held
1.5
quarters
Top 10 Avg Time Held
0.4
quarters
Top 20 Avg Time Held
0.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$38.5M |
| 2 |
Liquidia Corp
LQDA
|
+$268K |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$213K |
| 4 |
ArriVent BioPharma
AVBP
|
+$208K |
| 5 |
Krystal Biotech
KRYS
|
+$207K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sera Prognostics
SERA
|
+$4.87M |
| 2 |
DFTX
Definium Therapeutics
DFTX
|
+$613K |
| 3 |
Tyra Biosciences
TYRA
|
+$613K |
| 4 |
Cytokinetics
CYTK
|
+$547K |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$538K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 85.52% |
| 2 | Healthcare | 14.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Agios Pharmaceuticals
AGIO
$1.9B
| – | – |
-15,000
| Closed | -$507K | – |
|
|
APGE
77
DELISTED
Apogee Therapeutics
APGE
| – | – |
-2,500
| Closed | -$210K | – |
|
78
Celcuity
CELC
$3.32B
| – | – |
-2,000
| Closed | -$228K | – |
|
79
Compass Therapeutics
CMPX
$179M
| – | – |
-30,000
| Closed | -$159K | – |
|
|
80
Cytokinetics
CYTK
$8.75B
| – | – |
-8,300
| Closed | -$547K | – |
|
81
Erasca
ERAS
$5.61B
| – | – |
-17,327
| Closed | -$280K | – |
|
82
Inhibrx
INBX
$1.4B
| – | – |
-6,927
| Closed | -$466K | – |
|
|
KALV
83
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-10,795
| Closed | -$217K | – |
|
84
Legend Biotech
LEGN
$3.62B
| – | – |
-12,000
| Closed | -$217K | – |
|
85
Praxis Precision Medicines
PRAX
$7.26B
| – | – |
-1,500
| Closed | -$483K | – |
|
|
86
Sera Prognostics
SERA
$80.5M
| – | – |
-2,396,685
| Closed | -$4.87M | – |
|
87
Summit Therapeutics
SMMT
$14B
| – | – |
-10,223
| Closed | -$194K | – |
|
|
88
Tyra Biosciences
TYRA
$1.37B
| – | – |
-16,000
| Closed | -$613K | – |
|
89
United Therapeutics
UTHR
$23.6B
| – | – |
-350
| Closed | -$208K | – |
|
Similar funds
IJWM
TCPG
KCPT
DWS
RMSCM
AWP
NCPF
CFP
PSP Research's Q2 2026 Portfolio in Review
As of Q2 2026, PSP Research held 89 positions worth $188M, up 33% from $141M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
PSP Research deployed $25.8M of net new capital in Q2 2026, opening 10 new positions and adding to 1 existing holding. Its largest new stake was Liquidia Corp: 5,000 shares worth $399K.
By sector, the portfolio is most concentrated in Miscellaneous at 86% of assets, up from 76% a quarter earlier, followed by Healthcare.
On the sell side, the largest reduction was Definium Therapeutics, an estimated $613K trimmed.
- PSP Research's largest Q2 2026 buy was Liquidia Corp: 5,000 shares worth $399K.
- PSP Research added most to State Street SPDR S&P Biotech ETF in Q2 2026, an estimated $38.5M increase.
- PSP Research's biggest Q2 2026 reduction was Definium Therapeutics, cutting an estimated $613K.
- PSP Research fully exited Sera Prognostics in Q2 2026, selling an estimated $4.87M.
- PSP Research's ten largest holdings make up 88% of its $188M portfolio in Q2 2026.
- PSP Research opened 10 new positions and closed 14 in Q2 2026.
- PSP Research's portfolio value rose 33% quarter-over-quarter to $188M.
Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.